Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative FLOT vs Adjuvant XELOX for Gastric Cancer
NCT05264896Phase 3Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, fluorouracil, folinic acid, oxaliplatin in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by The Chinese University of Hong Kong. Started Mar 2022; status: recruiting.
02
Drugs
docetaxelfluorouracilfolinic acidoxaliplatin
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05264896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264896.